**Highlights of This Issue  4019**

**SPECIAL FEATURES  4021**

**CCR Translations**

- **4021** Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma  
  Katherine Woods and Jonathan Cebon  
  See article, p. 4228

**4024** Personalized Medicine: Through the Looking Glass of Functional Imaging  
  Raymond J. Hohl  
  See article, p. 4163

**CCR New Strategies**

- **4027** New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling  
  Gauri Varadhachary

**CCR Perspectives in Drug Approval**

- **4034** Is Conflict of Interest Becoming a Challenge for Institution-Based Institutional Review Boards?  
  Ralph S. Freedman and Ross McKinney, Jr

**Molecular Pathways**

- **4040** Molecular Pathways: ROS1 Fusion Proteins in Cancer  
  Kurtis D. Davies and Robert C. Doebele

**Reviews**

- **4046** HMGB1 in Cancer: Good, Bad, or Both?  
  Rui Kang, Qihong Zhang, Herbert J. Zeh III, Michael T. Lotze, and Daolin Tang

- **4058** Genomic Profiling Defines Subtypes of Prostate Cancer with the Potential for Therapeutic Stratification  
  Jamie R. Schoenborn, Pete Nelson, and Min Fang

**HUMAN CANCER BIOLOGY**

- **4067** microRNA 223 Is Upregulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1  
  Mirte Mayke Streppel, Shweta Pai, Nathaniel R. Campbell, Chaoxin Hu, Shinichi Yabuuchi, Marcia Irene Canto, Jean S. Wang, Elizabeth A. Montgomery, and Anirban Maitra

- **4079** Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin  
  Romain Remark, Marco Alifano, Isabelle Cremer, Audrey Lupo, Marie-Caroline Dieu-Nosjean, Marc Riquet, Lucile Crozet, Hanane Ouakrim, Jeremy Goc, Aurélie Cazes, Jean-François Flejou, Laure Gibault, Virginie Verkarre, Jean-François Régnard, Olivier-Nicolas Pagès, Stéphane Oudard, Berhard Mlecnik, Catherine Sautès-Fridman, Wolf-Herman Fridman, and Diane Damotte

- **4104** Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab  
  Christopher G. Smith, David Fisher, Bart Claes, Timothy S. Maughan, Shelley Idziasczczyk, Gillian Peuteman, Rebecca Harris, Michelle D. James, Angela Meade, Bharat Jasani, Richard A. Adams, Sarah Kenny, Richard Kaplan, Diether Lambrechts, and Jeremy P. Cheadle
miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities

Enrica Calura, Robert Fruscio, Lara Paracchini, Eliana Bignotti, Antonella Ravaggi, Paolo Martini, Gabriele Sales, Luca Beltrame, Luca Clivio, Lorenzo Ceppi, Mariacristina Di Marino, Ilaria Fusco Neri, Laura Zanotti, Duccio Cavalieri, Giorgio Cattoretti, Patrizia Perigo, Rodolfo Milani, Dionyssios Katsanos, Germana Tognon, Enrico Sartori, Sergio Pecorelli, Costantino Mangioni, Maurizio D’Incalci, Chiara Romualdi, and Sergio Marchini

CANCER THERAPY: PRECLINICAL

Anticancer Effects of Niclosamide in Human Glioblastoma
Anja Wieland, Daniel Trageser, Sabine Gogolok, Roman Reinfurt, Heike Hofer, Mihaela Keller, Anke Leinhaas, Ramona Schelle, Sabine Normann, Lil Klaas, Andreas Waha, Philipp Koch, Rolf Fimmers, Torsten Pietsch, Anthony T. Yachnis, David W. Pincus, Dennis A. Steindler, Oliver Brustle, Matthias Simon, and Bjorn Scheffler

Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain
Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin, Horacio Soto, Edward T. Ha, Shuichi Kamijima, Yuki Kato, Noriyuki Kasahara, Barbara M. Mueller, and Carol A. Kruse

Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillis, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, and S. Gail Eckhardt

IMAGING, DIAGNOSIS, PROGNOSIS


See commentary, p. 4024

A Poor Prognosis Subtype of HNSCC Is Consistently Observed across Methylome, Transcriptome, and miRNAome Analysis
Alain C. Jung, Sylvie Job, Sonia Ledrappier, Christine Macabre, Joseph Abecassis, Aurelien de Reynies, and Bohdan Waaslyk

A Functional Variant at 19q13.3, rs967591G>A, Is Associated with Shorter Survival of Early-Stage Lung Cancer
Hyo-Sung Jeon, Guang Jin, Hyo-Gyoung Kang, Yi Young Choi, Won Kee Lee, Jin Eun Choi, Eun Young Bae, Seung Soo Yoo, Shin Yup Lee, Eung Bae Lee, Young Tae Kim, Jaehee Lee, Seung-Ick Cha, Chang Ho Kim, Sanghoon Jhee, In San Kim, and Jae Yong Park

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Yi Zhang, Catherine A. Schnabel, Brock E. Schroeder, Piia-Lotta Jerevall, Rachel C. Jankowitz, Tommy Fornander, Olof Stal, Adam M. Brufsky, Dennis Sgroi, and Mark G. Erlander

Tumor Imaging and Interferon–Inducible Protein-10 Gene Transfer Using a Highly Efficient Transferrin-Conjugated Liposome System in Mice
Huiqin Zhuo, Yi Peng, Qin Yao, Nuo Zhou, Sufang Zhou, Jian He, Yuan Fang, Xi Li, Hongwei Jin, Xiaoling Lu, and Yongxiang Zhao

Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study
Eun Ju Cho, Jeong-Hoon Lee, Jeong-Ju Yoo, Won-Mook Choi, Min Jong Lee, Yuri Cho, Dong Hyeon Lee, Yun Bin Lee, Jung Hee Kwon, Su Jong Yu, Jung-Hwan Yoon, Chung Yong Kim, and Hyo-Suk Lee
A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
Craig L. Slingluff, Jr, Sandra Lee, Fengmin Zhao, Kimberly A. Chianese-Bullock, Walter C. Olson, Lisa H. Butterfield, Theresa L. Whiteside, Philip D. Leming, and John M. Kirkwood
See commentary, p. 4021

Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Elizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk, Leigh Marcus, Alberta Aikin, Patricia O. Whitcomb, Maria J. Merino, Maya Lodish, Eva Dombi, Seth M. Steinberg, Samuel A. Wells, and Frank M. Balis

Cyclophosphamide Induces a IFN-I–Associated Sterile Inflammatory Response Signature in Cancer Patients’ Blood Cells: Implications for Cancer Chemoimmunotherapy
Federica Moschella, Giovanni Fernando Torelli, Mara Valentini, Francesca Urbani, Carla Buccione, Maria Teresa Petrucci, Fiammetta Natalino, Filippo Belardelli, Robin Foà, and Enrico Proietti

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
Balaji Venugopal, Richard Baird, Rebecca S. Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles Phelps, John Camm, TR Jeffry Evans, Johann S. de Bono, and Udai Banerji

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatiou Ou, Sheheryar Kabraji, Mark M. Awad, Byohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrite, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, and Alice T. Shaw

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, lwyn Loh, Scott D. Patterson, Li Chen, and Jennifer L. Gansert

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter
Lorenza Rimassa, Jordi Bruix, Massimo Broggiini, and Armando Santoro

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Response
Paolo Michieli, Cristina Basilico, and Selma Pennacchietti

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Primary human glioblastoma cells reveal neuronal (green) and glial (red) differentiation potential. The image was obtained during multipotency and self-renewal analysis investigating antitumor effects of niclosamide. For details, see the article by Wieland and colleagues on page 4124 of this issue.